Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Three new #obesity drugshigh dose semaglutide, semaglutide plus cagrilintide, and oral orforglipronmay soon be approved in the US. JAMA Medical News Director Jennifer Abbasi and Lead Senior Staff Writer Rita Rubin examine how Weight Loss Efficacy of Cagrilintide and Semaglutide gutsandgrowth Tirzepatide Dosing Guide: 2026 Mounjaro & Zepbound The Peptide Toolkit Cagrilintide Peptide for Weight Loss Appetite Control & Metabolic Support